ISI

Biogen Idec, Isis partner on antisense program targeting myotonic dystrophy

Friday, June 29, 2012 03:12 PM

Weston, Mass.-based Biogen Idec and Isis Pharmaceuticals of Carlsbad, Calif., have entered into an exclusive, worldwide option and collaboration agreement to develop and commercialize a novel antisense drug for the treatment of myotonic dystrophy type 1 (DM1), also known as Steinert disease.

More... »

Scotland-based Innova Partnerships opens Boston office

Friday, June 15, 2012 12:02 PM

Innova Partnerships, a Scottish life sciences partnering and investment company, has opened of its first U.S. venture in Northborough, Mass., to enable the company to play a key role in the internationalization of life science companies in Scotland.

More... »

Piramal Healthcare to acquire Decision Resources Group

Thursday, May 17, 2012 10:04 AM

Piramal Healthcare, a pharmaceutical custom manufacturing company, has agreed to acquire Decision Resources Group (DRG), a healthcare information company of Burlington, Mass., from Providence Equity Partners for approximately $635 million.

More... »

IMS Health acquires DecisionView

Tuesday, April 24, 2012 03:13 PM

IMS Health of Danbury, Conn., has acquired DecisionView, a San Francisco-based software solutions company that helps life sciences organizations plan and track patient enrollment for clinical trials around the world. DecisionView offers decision support tools to improve the speed, efficiency and performance of clinical trial planning and management.

More... »

Illumina’s board unanimously rejects Roche’s offer

Wednesday, February 8, 2012 12:52 PM

Illumina’s board of directors has thoroughly reviewed Roche’s unsolicited tender offer with the assistance of its financial and legal advisors and, according to the company, has unanimously determined that the $44.50 per share cash offer is grossly inadequate in multiple respects, dramatically undervalues Illumina and is contrary to the best interests of Illumina’s stockholders.

More... »

VisionCare closes financing, makes board changes

Tuesday, January 24, 2012 12:51 PM

VisionCare Ophthalmic Technologies, a developer of advanced visual prosthetic devices, will close a Series E financing with Agate Medical Investments leading the expansion round.  Agate's managing general partner, Chanan Schneider, will join the VisionCare team as a board observer.

More... »

DecisionView unveils StudyOptimizer 4.4

Wednesday, January 11, 2012 03:42 PM

DecisionView, a leading provider of web software solutions, has released StudyOptimizer 4.4 to help clinical trial organizations plan, forecast and track patient enrollment.

More... »

Biogen Idec announces 2012 goals

Wednesday, January 11, 2012 11:15 AM

Growing its leadership position in multiple sclerosis (MS), advancing its late-state pipeline, leveraging R&D capabilities to grow its early-stage pipeline and preparing for potential launches of new high-impact therapies are among Biogen Idec’s recently announced 2012 strategic priorities.

More... »

Biogen Idec and Isis Pharmaceuticals target spinal muscular atrophy

Friday, January 6, 2012 09:58 AM

Biogen Idec and Isis Pharmaceuticals have entered into an exclusive, global option and partnership agreement under which they will jointly develop and commercialize ISIS-SMNRx, an antisense investigational drug that treats spinal muscular atrophy (SMA) by compensating for the underlying genetic defect that causes the disease.

More... »

Isis initates phase I spinal muscular atrophy study

Monday, December 19, 2011 11:34 AM

Isis Pharmaceuticals has initiated a phase I study of ISIS-SMNRx in patients with spinal muscular atrophy (SMA).  SMA is a severe motor-neuron disease that is the leading genetic cause of infant mortality. Isis is developing ISIS-SMNRx as a potential treatment for all types of SMA.

More... »